SUMO Therapeutics is a biotech startup developing first-in-line peptide inhibitors derived from the human SUMO protein to treat neurodegenerative diseases, with a focus on Alzheimer’s and Parkinson’s Disease. Using the proprietary peptide stabilization technology, aim to pioneer long-acting target-specific cyclized peptide therapeutics with enhanced serum stability and therapeutic efficacy.
The pipeline of peptide therapeutics interact with the monomers of the disease proteins to block early-stage aggregation to treat aggregation-associated neurodegenerative diseases.
Disclaimer: Any opinions, findings, conclusions or recommendations expressed in this material/event (or by members of the project team) do not reflect the views of the Government of the Hong Kong Special Administrative Region, the Innovation and Technology Commission or the General Support Programme Vetting Committee of the Innovation and Technology Fund.
© Designed by WHALE CASTLE IT CONSULTANT, Powered by MAGIC SQUARE STUDIO